NCT00548912

Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

Cardiac Magnetic Resonance Imaging in Hemodialysis Patients

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Dawnmarie DeFazio · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass

Detailed description

Dialysis patients have significant morbidity and mortality associated with left ventricular hypertrophy and cardiac failure. Aldosterone may have an important role in the development of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial effects of aldosterone antagonists on myocardial hypertrophy, and human studies have shown significant survival benefit in a non-dialysis population with congestive heart failure. This study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on cardiac hypertrophy in the end-stage renal disease population.

Conditions

• Kidney Failure, Chronic

Interventions

Type	Name	Description
DRUG	Spironolactone

Timeline

• Start date: 2007-10-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2007-10-24
• Last updated: 2021-12-09

Locations

1 site across 1 country: United States